Evidence map›Paper›PMID 41184153›Full record

SynthesisBMJ sexual & reproductive health2025

Safety of repeated use of emergency contraceptive pills in the same menstrual cycle: a systematic review.

Petrus Schonken Steyn, Erin Fleurant, Emma Marie Smith, James N Kiarie

Abstract readSystematic Review
In one paragraph

Synthesis in BMJ sexual & reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Petrus Schonken SteynUNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland steynp@who.int.ORCID http://orcid.org/0000-0001-8300-7985
Erin FleurantDivision of Complex Family Planning, Department of Obstetrics and Gynecology, Endeavor Health, Evanston, Illinois, USA.ORCID http://orcid.org/0009-0002-8973-7350
Emma Marie SmithDepartment of Obstetrics & Gynecology, Complex Family Planning, Kaiser Permanent Medical Centre, Oakland, California, USA.ORCID http://orcid.org/0000-0001-6430-4415
James N KiarieUNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.ORCID http://orcid.org/0000-0003-4180-7858

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundEmergency contraception refers to contraceptive methods used following unprotected sexual intercourse.

objectiveTo review the literature on safety of repeated use of emergency contraceptive pills (ECPs) in the same menstrual cycle.

methodsWe searched multiple databases from inception through February 2024 for articles on repeated ECP use. We assessed the risk of bias for each study and certainty of evidence for all outcomes.

resultsFrom 4565 articles identified, six met the inclusion criteria. Four studies of repeated levonorgestrel (LNG)-ECP use provided very low certainty evidence. Among women who became pregnant after at least one use of LNG-ECP in the conception cycle, women with ectopic pregnancy had increased odds of repeated LNG-ECP use in the conception cycle compared with women with intrauterine pregnancy (adjusted OR (aOR) 2.5, 95% CI 1.0 to 6.2). One non-comparative study reported few serious adverse events with repeated pericoital use of LNG-ECP, and two cohort studies of LNG-ECP failure found no differences in pregnancy, fetal/neonatal, infant or child outcomes comparing higher (2.25-9 mg LNG) and lower (0.75-1.5 mg LNG) doses in the conception cycle. Two studies of repeated ulipristal acetate (UPA) use provided very low certainty evidence. One non-comparative study observed no serious adverse events, no abnormal laboratory results and normal endometrial biopsies with UPA (30 mg, 4-6 doses/month). One randomised controlled trial in a clinical setting observed no serious adverse events with UPA (10 mg, 20 mg or 50 mg for 10 days) compared with placebo.

conclusionEvidence on the safety of repeated ECP use is limited and of very low certainty, but overall does not suggest safety concerns.

Indexed as

Contraception, PostcoitalContraceptives, PostcoitalMenstrual CycleAdultFemaleHumansLevonorgestrelPregnancyContraceptives, PostcoitalLevonorgestrelcontraceptives, postcoitalPatient Safety

Identifiers

PMID41184153
PMCPMC12703341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.